StockpollyBeta
Get App
Popularity #2,970
LXEO · NASDAQ · Biotechnology

Lexeo Therapeutics (LXEO)

Develops genetic medicines for inherited cardiovascular disease and select CNS disorders.

$4.07
After hours0.00 (0.00%)
At close$4.07(−0.25%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000010
Gross profit0000000000−10
201523243227343122232228
Research & development17816172318171516161619
37878917166779
General & administrative37878917166779
Other expenses0000000000−10
Operating income−20−15−23−24−32−27−34−31−22−23−22−28
012221151222
Interest income012221111222
Interest expense000000000000
Other non-operating income0−1−2−2−2−1−1−5−1−2−2−2
Income before tax−20−14−22−21−29−26−33−26−20−21−20−26
Net income from continuing operations−20−14−22−21−29−26−33−26−20−21−20−26
Net income−20−14−22−21−29−26−33−26−20−21−20−26
EPS, basic−$0.80−$0.52−$0.77−$0.64−$0.89−$0.78−$0.99−$0.60−$0.33−$0.27−$0.25−$0.30
EPS, diluted−$0.80−$0.52−$0.77−$0.64−$0.89−$0.78−$0.99−$0.60−$0.33−$0.27−$0.25−$0.30
Weighted average shares, basic252728333333334461768186
Weighted average shares, diluted252728333333334461768186
EBITDA−20−14−21−21−29−25−32−26−20−20−20−26
Depreciation & amortization000011111110
EBIT−20−14−22−21−29−26−33−26−20−21−20−26